MusaYilmazMD

PubMed

• Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.
  Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia
  Haematologica. 2024-12-12
• Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
  Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, Yesid Alvarado, Gautam Borthakur
  Cancer. 2024-11-25
• 1 citations
  Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
  Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, Tapan Kadia, Naval Daver
  Haematologica. 2024-11-01

Abstracts/Posters

• Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myel...
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Musa E. Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Musa Yilmaz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019